U.S. medical discount service provider GoodRx Holdings, Inc. recently announced the launch of an innovative subsidy program for self-insured employers.

Through this program, companies can reimburse employees for part of the cost of Eli Lilly's weight loss injection pen, Zepbound Kwikpen, allowing patients to pay an amount close to the $449 discounted price listed on the GoodRx platform. This initiative will help self-insured employers control healthcare costs while providing employees with more affordable weight loss treatment options. Zepbound, a new GLP-1 receptor agonist launched by Eli Lilly, typically has a standard market retail price of over $1,000, but through GoodRx's subsidy mechanism, employees' out-of-pocket expenses will be significantly reduced. Industry analysts point out that this move is expected to increase GoodRx's market share in the corporate health benefits sector, while also providing Eli Lilly with a new path to expand Zepbound's market penetration. Currently, this subsidy program is open for applications from self-insured employers nationwide, and companies can flexibly set subsidy amounts based on employee needs.